Targeting the C/EBPβ-PRAME-EZH2 complex modulates the Netrin-4/AKT axis to inhibit renal cancer tumorigenesis and...

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Cancer-testis antigens are promising therapeutic targets, but their roles in cancer progression remain unclear.
• Clear cell renal cell carcinoma (ccRCC) metastasis is a significant clinical challenge.
• Understanding the molecular mechanisms driving ccRCC metastasis is crucial for developing effective treatments.

Purpose of the Study:

• To identify novel regulators of metastasis in ccRCC.
• To elucidate the molecular mechanisms by which PRAME promotes ccRCC progression.
• To explore therapeutic strategies targeting PRAME in ccRCC.

Main Methods:

• Comprehensive bioinformatics analyses to identify potential metastasis regulators.
• RNA-sequencing (RNA-Seq) and functional studies to investigate downstream effectors.
• Mechanism analyses involving protein-protein interactions, promoter occupancy, and epigenetic modifications (H3K27 trimethylation).
• Development and testing of a cell-permeable peptide to disrupt the PRAME complex.

Main Results:

• PRAME, a nuclear cancer-testis antigen, was identified as a regulator of metastasis in ccRCC.
• Netrin-4 (NTN4) was identified as a key downstream effector of PRAME, involved in its oncogenic functions.
• PRAME forms a ternary complex with C/EBPβ and EZH2, leading to epigenetic repression of NTN4 expression via H3K27 trimethylation.
• This complex promotes AKT activation and ccRCC development, with C/EBPβ stimulating PRAME expression.
• A cell-permeable peptide successfully inhibited ccRCC progression in preclinical models.

Conclusions:

• PRAME plays a critical role in ccRCC metastasis by mediating the C/EBPβ-EZH2-NTN4 regulatory axis.
• The findings provide novel insights into the epigenetic regulation of metastasis in ccRCC.
• Targeting the C/EBPβ-PRAME-EZH2 complex represents a promising therapeutic strategy for ccRCC.